CurrentUnitedHealthcarePolicy CS132ID.C

Noncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (Idaho)

State-specific medical policy for Idaho governing coverage and medical necessity of noncontact warming (NNWT), low-frequency ultrasound therapy, and noncontact real-time fluorescence wound imaging for bacterial detection; applies to UnitedHealthcare Idaho plans including Idaho Medicaid Plus.

Policy Summary

PayerUnitedHealthcare

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (Idaho)

Policy CodePolicy CS132ID.C

Change TypeNo material changes

Effective DateDec 1, 2025

Next Review DateN/A

Key ActionFor low-frequency ultrasound (code 97610) follow Idaho Medicaid Provider Handbook, Therapy Services, Chapter 5.1 for authorization and medical necessity criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3technologies discussed

Idahostate-specific

0598T, 97610, A6000codes listed

46-138example study cohorts

12/01/2025policy effective

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations and Rationale

Coverage determinations

Coverage stance by technology

Low-frequency ultrasound therapy (Idaho): Refer to Idaho Medicaid Provider Handbook, Therapy Services, Chapter 5.1: Active Wound Care Management (OT/PT) for medical necessity clinical coverage criteria for low-frequency ultrasound therapy for treating wounds.

State-specific criteria govern authorization and medical necessity for ultrasound-based wound therapy.

Noncontact normothermic wound therapy (NNWT): Unproven and not medically necessary for treating wounds due to insufficient evidence of efficacy.

Policy concludes lack of robust randomized trial evidence and methodological limitations in available studies.

Noncontact real-time fluorescence wound imaging: Unproven and not medically necessary for detecting bacterial presence and guiding care due to insufficient evidence of safety and/or efficacy to demonstrate improved patient-centered outcomes.

Diagnostic accuracy studies show higher sensitivity for moderate-to-heavy bacterial loads, but clinical utility for improving wound healing or antibiotic stewardship has not been established.

Diagnostic accuracy vs clinical outcome evidence

Evidence summary and implications for coverage

Evidence for diagnostic accuracy vs outcomes: Small randomized and observational studies report improved detection of moderate-to-heavy bacterial loads with autofluorescence imaging and some signals of greater wound-area reduction or higher healing proportions in pilot studies (e.g., Rahma et al. pilot RCT). However, systematic assessments (ECRI; NICE summaries) conclude the evidence is inconclusive for demonstrating improvement in patient-centered outcomes; larger, well-powered randomized trials are needed to establish clinical utility.

Rahma et al. (pilot RCT) showed higher proportion healed at 12 weeks in the autofluorescence arm but was underpowered; Le et al. and ECRI note improved sensitivity for bacterial loads but do not demonstrate outcome benefit.

The policy designates noncontact normothermic wound therapy (NNWT) and noncontact real-time fluorescence wound imaging as unproven and not medically necessary for treating wounds. This determination is based on an overall insufficient evidence of efficacy demonstrating meaningful improvement in patient-centered outcomes.

Available assessments, including an ECRI evidence review, conclude the evidence for the MolecuLight i:X system is inconclusive; studies to date do not provide sufficient evidence that use of the device reduces wound closure time or demonstrably improves antibiotic stewardship. The existing observational studies highlight improved detection of moderate-to-heavy bacterial loads but do not establish clinical utility for improved patient outcomes.

Accordingly, NNWT and noncontact real-time fluorescence wound imaging for the purpose of detecting bacterial presence are considered not medically necessary because current evidence does not support their safety and/or efficacy for improving clinical outcomes.

Routine use of fluorescence imaging solely with the intent to improve wound closure rates or to guide antibiotic prescribing is unproven. Diagnostic studies report higher sensitivity for detecting bacterial loads, but these data do not demonstrate that fluorescence-guided management leads to faster wound healing or better antibiotic stewardship; therefore routine coverage for those intended benefits is not established.

This Medical Policy is provided for informational purposes. Coverage determinations must still conform to the member's applicable federal, state, or contractual benefit plan; in the event of a conflict, the terms of those benefit plans govern coverage decisions.

Applicable Codes and Device Clearances

Applicable Procedure and Supply Codesmixed

0598T	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (e.g., lower extremity)
97610	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (e.g., upper extremity) (List separately in addition to code for primary procedure).
97610	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day
A6000	Noncontact wound-warming wound cover for use with the noncontact wound-warming device and warming card
E0231	Noncontact wound-warming device (temperature control unit, AC adapter and power cord) for use with warming card and wound cover
E0232	Warming card for use with the noncontact wound-warming device and noncontact wound warming- wound cover

FDA 510(k) references and predicate numbersmixed

K191371	510(k) premarket notification number referenced for MolecuLight i:X
K050129	510(k) reference for MIST/UltraMIST device (example FDA reference cited)

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required (Idaho-specific guidance)

Prior authorization may be required for low-frequency ultrasound (MIST/Ultrasound wound therapy) when administered under plans subject to Idaho-specific rules. This policy applies to the state of Idaho, including Idaho Medicaid Plus plans; refer to Idaho Medicaid Provider Handbook, Therapy Services, Chapter 5.1: Active Wound Care Management (OT/PT) for state-specific prior authorization criteria.

Codes commonly involved: 97610 (low frequency non-contact ultrasound) — see Applicable Codes for reference
Check plan/provider portal for prior authorization submission workflow and required clinical documentation

Prior Authorization

Prior Authorization Guidance — investigational technologies

If a payer treats noncontact real-time fluorescence wound imaging or noncontact normothermic wound therapy (NNWT) as investigational or not medically necessary, establish a prior authorization workflow that requires submission of supporting clinical evidence. Because evidence is limited, prior authorization requests should include rationale for use and documentation of prior standard care measures.

Device and Therapy Definitions

Noncontact normothermic wound therapy (NNWT) — definition

DefinitionNoncontact normothermic wound therapy (NNWT) uses a noncontact wound cover and a warming unit to apply radiant heat and maintain near‑100% relative humidity over a wound to raise wound temperature, with the intent of increasing blood flow and oxygenation.

ModalityDelivered via a noncontact wound cover plus a temperature control unit (wound-warming device and warming card).

Therapeutic intentRaise local wound temperature to increase perfusion and oxygen delivery to support wound healing.

Regulatory contextDevices such as Warm-Up Active Wound Therapy have received FDA 510(k) clearance historically as occlusive heated dressings (informational).

Fluorescence wound imaging (MolecuLight i:X) — definition

Definition

Background and Technical Overview

Noncontact normothermic wound therapy (NNWT) uses a noncontact wound cover and warming unit to apply radiant heat and maintain humidity with the goal of raising wound temperature to increase local blood flow and oxygenation. The proposed rationale is that a warmer, humid microenvironment may support healing by improving perfusion and cellular function, but the policy concludes current clinical evidence is insufficient to demonstrate treatment benefit.

Policy Summary

PayerUnitedHealthcare

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (Idaho)

Policy CodePolicy CS132ID.C

Change TypeNo material changes

Effective DateDec 1, 2025

Next Review DateN/A

Key ActionFor low-frequency ultrasound (code 97610) follow Idaho Medicaid Provider Handbook, Therapy Services, Chapter 5.1 for authorization and medical necessity criteria.

SourceLink

On This Page

Include device model and FDA 510(k) clearance documentation when available (e.g., MolecuLight i:X K191371)

Provide detailed wound history, prior treatments, and rationale for adjunctive modality

Denial Risk

Denial Risk — NNWT and Fluorescence Imaging

Noncontact normothermic wound therapy (NNWT) and noncontact real-time fluorescence wound imaging are designated as unproven and not medically necessary in this policy due to insufficient evidence; coverage may be denied when billed for these technologies.

Expected denial risk for claims using codes: 0598T (MolecuLight i:X first site) and associated codes where plan deems service not medically necessary
Providers should anticipate denials if documentation does not demonstrate plan-covered indications or applicable exception criteria

Denial Risk

Insufficient Evidence for Outcome Improvement

Limited and inconclusive evidence that fluorescence imaging or NNWT improve patient-centered outcomes (wound closure, infection-related outcomes, or antibiotic stewardship) may be a basis for denying coverage; include high-quality clinical rationale when requesting coverage.

ECRI and NICE report limited evidence of improved wound closure or clinical outcomes for MolecuLight i:X
Randomized controlled trial data are lacking; observational accuracy studies do not demonstrate patient outcome benefit

Note

Benefit Plan Governance — follow applicable benefit language

When there is any conflict between this policy and federal, state, or contractual benefit requirements, the applicable benefit plan language governs coverage decisions. Confirm and document the member's specific benefit plan, state mandate, or contractual provisions when submitting authorization requests or appeals.

Reference the member's benefit plan and applicable federal/state contractual requirements in the request
In case of conflict, federal/state/contractual requirements supersede this Medical Policy

Documentation Required

Document Device and Clearance

Document the specific device model and FDA 510(k) clearance in the clinical record when using fluorescence imaging or device-based adjuncts to wound care (for example, document MolecuLight i:X and reference K191371). FDA clearance alone does not guarantee coverage but should be included with clinical rationale.

Include device make/model and 510(k) number (e.g., MolecuLight i:X K191371) in the medical record and authorization submission
Attach or reference FDA 510(k) documentation when available

Documentation Required

Documentation of Benefit Applicability

Document applicability of benefit rules and any relevant federal/state/contractual requirements in the patient's record and prior authorization submission. Explicitly state which benefit language or state program (e.g., Idaho Medicaid Plus) is being relied upon for coverage determination.

State-specific programs (Idaho Medicaid Plus) should be referenced when applicable
Document member's plan, state of residence, and any cited contractual language in the request

Note

Adjuncts After Standard Care — optimize and document primary wound management first

Adjunctive technologies (low-frequency ultrasound, fluorescence imaging, warming therapy) should be considered only after standard wound care measures have been optimized. Standard care includes offloading (for DFU), adequate compression (for venous ulcers), regular debridement, appropriate dressings, and control of infection and ischemia. Document prior standard care and response before requesting adjunctive therapy.

Ensure documentation of: offloading, debridement, compression therapy (if VU), dressings, infection control, and vascular assessment
State that adjunctive use is being requested after failure or inadequate response to standard care measures

Handheld fluorescence imaging (MolecuLight i:X) is a point‑of‑care device that illuminates wounds with violet light to capture and document bacterial fluorescence in real time to assist diagnostic and treatment decisions.

Primary functionDetects and documents presence and location of bacteria in wounds and surrounding tissue by visualizing fluorescent characteristics.

Clinical roleIntended to inform wound assessment, sampling, and targeted treatment decisions but evidence for improved patient‑centered outcomes is inconclusive per clinical assessments.

Regulatory noteThe MolecuLight i:X device was cleared by the FDA via 510(k) (K191371) — clearance is informational and not itself a coverage determination.

Autofluorescence imaging (MolecuLight i:X) — device definition and intended use

DefinitionAutofluorescence imaging (MolecuLight i:X) is a handheld, point‑of‑care device that uses bacterial autofluorescence to visualize moderate‑to‑heavy bacterial loads in wounds and guide sampling and targeted treatment.

Diagnostic performanceStudies report increased sensitivity and accuracy for detecting moderate‑to‑heavy bacterial loads when used with clinical assessment versus clinical assessment alone.

Intended useUsed to identify wounds with elevated bacterial load to assist clinician decision‑making (e.g., targeted debridement or sampling), though clinical utility for improving wound closure or antibiotic stewardship is not yet established.

Evidence limitationsClinical evidence assessments (ECRI, NICE) conclude current data are insufficient to demonstrate improvement in patient‑centered outcomes and recommend further larger RCTs.

MIST / UltraMIST therapy — definition and regulatory context

DefinitionMIST/UltraMIST therapy refers to low‑energy ultrasound‑generated mist devices that produce a fine mist of saline by ultrasound to promote wound healing through wound cleansing and maintenance debridement (removal of slough, fibrin, exudate, and bacteria).

MechanismUses low‑energy ultrasound to generate a mist intended to cleanse wounds and assist maintenance debridement without direct contact.

FDA classificationRegulated as Class II devices and cleared via the FDA 510(k) process (examples: MIST Therapy System, UltraMIST K050129/K140782).

Indication languageApproved indication includes promoting wound healing through wound cleansing and maintenance debridement by removal of yellow slough, fibrin, tissue exudates, and bacteria.

Bacterial fluorescence imaging — device description and clinical application

DefinitionBacterial fluorescence imaging denotes portable autofluorescence devices (e.g., MolecuLight i:X) that provide point‑of‑care visualization of bacterial load to guide wound assessment and targeted debridement.

Clinical applicationIntended to augment clinical signs and symptoms (CSS) assessment to improve detection of moderate‑to‑heavy bacterial loads and guide sampling and treatment.

Reported benefitsPilot and observational studies report improved detection sensitivity and diagnostic accuracy compared with CSS assessment alone, identifying wounds with bacterial loads missed by clinical assessment.

LimitationsEvidence gaps include small sample sizes, limited longitudinal outcome data, and lack of definitive trials demonstrating improved patient‑centered outcomes.

Low‑frequency therapeutic ultrasound (20–40 kHz) — definition

DefinitionLow‑frequency therapeutic ultrasound refers to noncontact or contact ultrasound therapies operating in the ~20–40 kHz range used as adjunctive treatments to promote chronic wound healing and assist debridement.

Clinical roleUsed as an adjunct to standard wound care (offloading, debridement, dressings, compression, infection/ischemia control) to support healing, pain reduction, or wound bed preparation.

EvidenceSystematic reviews and randomized trials have evaluated low‑frequency ultrasound for venous leg ulcers and other chronic wounds, with mixed results cited in the literature.

Authorization note (Idaho)State‑specific medical necessity criteria and authorization for low‑frequency ultrasound therapy (CPT/HCPCS mapping: 97610 referenced) are governed by the Idaho Medicaid Provider Handbook, Therapy Services, Chapter 5.1.